
Gilead Sciences GILD
€ 112.68
0.17%
Quartalsbericht 2026-Q1
hinzugefügt 07.05.2026
Gilead Sciences Langfristiger Schuldenstrom 2011-2026 | GILD
Langfristiger Schuldenstrom Jährlich Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 M | 113 M | 125 M | 111 M | 101 M | 107 M | 99 M | 2.75 B | 2.75 B | - | 983 M | 483 M | 2.7 B | -1.17 B | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.75 B | -1.17 B | 711 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
102 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.14 | 0.16 % | $ 653 M | ||
|
Eton Pharmaceuticals
ETON
|
65 K | $ 35.05 | 1.73 % | $ 943 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 22.24 | 9.5 % | $ 288 M | ||
|
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
13 M | - | - | $ 344 M | ||
|
IMV
IMV
|
320 K | - | - | $ 13.1 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 91.28 | 1.02 % | $ 22.1 B | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 8.12 | -0.92 % | $ 5.52 B | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.66 | 2.16 % | $ 442 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
3.04 M | $ 0.88 | 3.88 % | $ 147 M | ||
|
Compugen Ltd.
CGEN
|
521 K | $ 2.62 | -3.33 % | $ 245 M | ||
|
Anika Therapeutics
ANIK
|
2.05 M | $ 15.05 | -0.59 % | $ 216 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Incyte Corporation
INCY
|
5.7 M | $ 97.57 | 0.5 % | $ 19 B | ||
|
Ionis Pharmaceuticals
IONS
|
9.51 M | $ 76.17 | 1.47 % | $ 12.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 3.44 | 3.61 % | $ 5.66 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.6 | 5.63 % | $ 187 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
4.16 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 20.96 | 2.37 % | $ 2.67 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M |